国产精品av在线观看不_日韩久久美女毛片_黄色网站在线性爱视频_9691精品人妻无码久久久_成年AV免费网址大全超清_亚洲aⅴ天堂无码_曰本裸色私人影院噜噜噜影院_另类视频无码视频国产精品_网红三级在线播放_美腿丝袜在线观看

Entries by

EISAI TO PRESENT RESULTS OF PHASE Ib/II STUDY OF ANTICANCER AGENT LENVIMA? (LENVATINIB) IN COMBINATION WITH ANTI-PD-1 ANTIBODY PEMBROLIZUMAB FOR THE TREATMENT OF ENDOMETRIAL CARCINOMA AT 53RD ASCO ANN

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced the first results for metastatic endometrial carcinoma obtained from a Phase Ib/II study (Study 111) of its in-house developed multi-kinase inhibitor lenvatinib mesylate (product names: Lenvima? / Kisplyx?, “lenvatinib”) in combination with the MSD (known as Merck & Co., Inc, Kenilworth, NJ, USA in the United States and Canada) anti-PD-1 antibody pembrolizumab (brand name: KEYTRUDA?*), during a presentation at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States. The two companies are collaborating to develop this combination therapy. Study 111 is being conducted to evaluate the activity of the lenvatinib/pembrolizumab combination in select solid tumors.

2017/6/5 by

INITIATIVES FOR DEVELOPING NEW MEDICINES FOR NEGLECTED TROPICAL DISEASES AND MALARIA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced that it will grant a total of 500 million yen to the Global Health Innovative Technology Fund (“GHIT Fund”) to fund the second phase of its activities, which will take place in the five-year period from FY 2018 to FY 2022. The GHIT Fund is a public-private partnership, co-established in April 2013 by multiple Japanese pharmaceutical companies (including Eisai), the Japanese government, and the Bill & Melinda Gates Foundation, for the purpose of accelerating development of new medicines to cure infectious diseases in developing and emerging countries by facilitating collaboration between research organizations in Japan and overseas.

2017/6/1 by

Eisai (China)’s Total 1.98 Million RMB Worth of Medicine Donation to “Health to Countryside” Activity for Four Consecutive Years

On April 19, 2017, Eisai China Inc. (hereinafter referred to as: Eisai (China)) was invited to attend the “Health to Countryside” activity held in Yudu County, Jiangxi Province by the National Committee for Education, Science, Culture, Health and Sports of Chinese People’s Political Consultative Conference (CPPCC), and donated medicines worth RMB540,000 yuan to the local hospitals. According to the statistics, Eisai (China), practicing the philosophy of hhc (human health care) all along, donated medicines worth RMB450,000, RMB490,000, RMB500,000 and RMB540,000 respectively to this activity from the year 2014 to 2017, with the total worth of medicines reaching up to RMB1.98 million yuan.

2017/4/19 by

EISAI AND MEIJI ENTER INTO LICENSING AGREEMENT CONCERNING PARKINSON’S DISEASE DRUG SAFINAMIDE IN JAPAN AND ASIA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; CEO: Daikichiro Kobayashi, “Meiji”) announced today that they have entered into a license agreement for the commercialization of safinamide (development code: ME2125) for the treatment of Parkinson’s disease in Japan and Asia. Safinamide is currently under clinical development by Meiji in Japan.

2017/4/5 by

EISAI PRESENTS DATA OF MECHANISMS OF ACTION RELATING TO TUMOR IMMUNE RESPONSE REGARDING COMBINATION OF ANTICANCER AGENT LENVATINIB WITH ANTI-PD-1 ANTIBODY AT AACR 108TH ANNUAL MEETING

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has presented the latest research data regarding a mechanism of action that led to increased anti-tumor activity in mouse models which had been dosed with a combination of the in-house developed anticancer agent lenvatinib mesylate (lenvatinib) and an anti-mouse PD-1 antibody, at the American Association for Cancer Research (AACR) 108th Annual Meeting.

2017/4/5 by

GERMAN FEDERAL JOINT COMMITTEE (G-BA) CONFIRMS ADDITIONAL BENEFIT OF ANTICANCER AGENT KISPLYX? (LENVATINIB MESYLATE) IN TREATMENT OF ADVANCED RENAL CELL CARCINOMA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai” ) announced today that the German Federal Joint Committee (G-BA) has confirmed the additional benefit of in-house developed anticancer agent Kisplyx??(lenvatinib mesylate) in combination with everolimus for the treatment of advanced renal cell carcinoma (RCC) compared to everolimus alone in its assessment for insurance reimbursement. Based on this additional benefit assessment, price negotiations with the Head Association of German Sick Funds (GKV-SV) will be conducted, and a reimbursement price has to be agreed.?

2017/3/28 by

EISAI ENTERS INTO MARKETING AND DISTRIBUTION AGREEMENT WITH ORION CONCERNING PARKINSON’S DISEASE DRUGS IN CHINA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has entered into a marketing and distribution agreement with Orion Corporation (Headquarters: Espoo, Finland; CEO: Timo Lappalainen, “Orion”) concerning its Parkinson’s disease treatments Comtan?(entacapone) and Stalevo?(levodopa/entacapone/carbidopa combination agent) in China.

2017/2/16 by

EISAI ACQUIRES ALL GLOBAL DEVELOPMENT AND MARKETING RIGHTS FOR CHRONIC WEIGHT MANAGEMENT TREATMENT LORCASERIN

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) announced today that, in association with its U.S. pharmaceutical subsidiary Eisai Inc. (collectively, “Eisai”), it has reached an agreement with Arena Pharmaceuticals, Inc. (Headquarters: California, United States, President and CEO: Amit D. Munshi) to revise the November 2013 marketing and supply agreement it concluded with Arena’s wholly owned subsidiary, Arena Pharmaceuticals GmbH (collectively, “Arena”), for the chronic weight management treatment lorcaserin hydrochloride (generic name, U.S. brand name: BELVIQ? / BELVIQ XR?, “BELVIQ”). Under the new agreement, Eisai acquires all of Arena’s rights to develop and market BELVIQ.

2017/1/5 by

ANTICANCER AGENT TREAKISYM? APPROVED IN JAPAN FOR ADDITIONAL INDICATION AS FIRST-LINE TREATMENT FOR LOW-GRADE B-CELL NON-HODGKIN′S LYMPHOMA AND MANTLE CELL LYMPHOMA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the anticancer agent TREAKISYM? (generic name: bendamustine hydrochloride) has been approved in Japan for an additional indication as first-line treatment for low-grade B-cell non-Hodgkin′s lymphoma and mantle cell lymphoma (MCL). TREAKISYM is the subject of a licensing agreement concluded between Eisai and SymBio Pharmaceuticals Limited (Headquarters: Tokyo, Representative Director, President & CEO: Fuminori Yoshida, “SymBio”). Through the approval of this additional indication, TREAKISYM will now be available for adjunctive use with rituximab for untreated low-grade B-cell non-Hodgkin′s lymphoma and MCL.

2016/12/19 by